O. Gallego et al., Drug resistance in patients experiencing early virological failure under atriple combination including indinavir, AIDS, 15(13), 2001, pp. 1701-1706
Objective: To assess the pattern of drug resistance mutations selected in H
IV-1-infected patients failing a first line triple combination therapy incl
uding indinavir.
Patients and methods: Plasma samples from 87 patients collected at the time
of the first virological rebound (> 50 HIV-RNA copies/ml) were examined fo
r the presence of drug-resistant genotypes.
Results: The mean level of plasma viraemia at rebound was 7824 HIV-1 RNA co
pies/ ml in 73 subjects with good compliance, whereas it was 359 460 HIV-1
RNA copies/ ml in 14 patients who admitted to poor adherence. Genetic seque
nce analysis yielded results for 51 (70%) of the patients having good adher
ence. More than half of them (26/51, 51%) carried primary mutations associa
ted with resistance to nucleoside analogues. In contrast, primary protease
inhibitor resistance mutations were recognized less frequently (14/51, 27%;
P < 0.05). Moreover, in 23 (45%) patients there was no evidence of drug-re
sistant viruses at all. The most frequent drug-resistant genotypes in the r
everse transcriptase gene were at codons 184 (n = 19), 215 (n = 14) and 41
(n = 8), whereas for the protease they were at codons 46 (n = 10), 82 (n =
9) and 90 (n = 7). No resistance genotypes were found among non-compliant p
atients.
Conclusion: The overall rate of drug-resistant HIV genotypes was 38% (28/73
) in patients with good adherence and who were experiencing a first virolog
ical failure under a triple combination regimen including indinavir; resist
ance to nucleoside analogues was more frequent than resistance to indinavir
. Therefore, treatment intensification in those patients without resistance
, or a selective substitution of nucleosides in those with resistance limit
ed to these compounds, might be justified. (C) 2001 Lippincott Williams & W
ilkins.